Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$27.45
--
Market closed
$27.45
--
Day’s Range― - ―
52-Week Range$13.18 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$478.68M
Enterprise Value$253.29M
Total Cash (Recent Filing)$211.46M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)―
Beta0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue25.33
Enterprise Value/Gross Profit27.31
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$37.60Price Target Upside36.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Material Balance-sheet RepairA dramatic drop in debt and a swing to positive equity materially reduces leverage risk and increases optionality to fund mid-stage trials. This improvement strengthens financial resilience, lowers near-term refinancing pressure, and supports multi-year R&D execution if cash discipline continues.
Consistent Revenue ScalingSustained top-line growth across multiple years indicates commercial or partnership traction and a rising revenue base. Durable revenue expansion improves the company's ability to absorb R&D investment and narrows the gap to profitable scale if growth persists and gross margins remain healthy.
Pipeline Breadth With Multi-year RunwayHaving multiple mid-stage programs (EVO756 in other indications, EVO301 development) plus a stated cash runway to 2028 preserves the firm's ability to reallocate resources after a setback. Breadth across dermatology and neuroinflammation reduces single-indication reliance and supports longer-term value creation.
Bears Say
Rising Operating Cash BurnWorsening operating and free cash flow indicates growing financing needs and reduces margin for error on trials. Persistent, rising cash burn increases dilution or refinancing risk over the medium term unless revenue accelerates or expenses are cut materially.
Large, Persistent Net LossesSubstantial recurring losses reflect a cost base that outpaces current revenue and will slow the company's path to sustainable profitability. Over the medium term this necessitates either faster commercial scaling or sustained external funding, pressuring long-term shareholder returns.
Clinical Setback Reducing Addressable OpportunityHalting development in an indication removes a potential commercialization path and shortens the portfolio's near-term optionality. This raises execution risk as management must re-prioritize programs and recoup expected value in other indications, potentially delaying revenues and increasing spend.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.18 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $478.68M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.60 (36.98% Upside)
$37.60 (36.98% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-195.15%
Trailing 12-Months
Asset Growth
475.65%
Trailing 12-Months
Company Description
Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$37.60
▲(36.98% Upside)
Ownership Overview
52.56% Insiders
10.70% Mutual Funds
10.56% Other Institutional Investors
23.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---